Autolus Therapeutics Presents Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
Key Highlights
- ➤Autolus (AUTL) reports obe-cel improved SLEDAI-2K and achieved DORIS in most participants
- ➤100% of patients followed at least six months achieved DORIS despite severe baseline disease
- ➤Complete renal response reached 6/9 participants; no severe renal flares observed
- ➤No ICANS, HLH/IEC-HS, or high-grade CRS events among 15 infused patients
- ➤Phase II LUMINA trial evaluating obe-cel at a single 50×10⁶ dose in active lupus nephritis
Expert Statements
Matthias Will, Chief Development Officer of Autolus
“There is a critical unmet need for treatments that work in severe refractory disease of srSLE and lupus nephritis (LN). In the ongoing Phase 1 CARLYSLE trial, we continue to see deep, durable responses with obe-cel and are particularly encouraged by the continued favorable safety profile, in up to 25 months of follow up in adult patients at the data cutoff. We believe these encouraging data underscore the potential for obe-cel as an important treatment option in autoimmune disease.”
* Data show clinically significant improvements in SLEDAI-2K scores and achievement of DORIS in most patients, despite severe disease activity at baseline * In 15 patients evaluable for safety, obe-cel was well-tolerated with no ICANS, IEC-HS or Grade ≥3 CRS events observed LONDON and GAITHERSBURG, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced longer-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (srSLE), was presented today during a poster session at the American College of Rheumatology (ACR) Convergence 2026.
Dr. Matthias Will, Chief Development Officer of Autolus said, “There is a critical unmet need for treatments that work in severe refractory disease of srSLE and lupus nephritis (LN). In the ongoing Phase 1 CARLYSLE trial, we continue to see deep, durable responses with obe-cel and are particularly encouraged by the continued favorable safety profile, in up to 25 months of follow up in adult patients at the data cutoff. We believe these encouraging data underscore the potential for obe-cel as an important treatment option in autoimmune disease.”
Get started
Create a free account to read the full story.